Wed Sep 18 01:42:28 UTC 2024: ## Single Dose of Existing Vaccine Shows Promise Against Mpox: New Study
**Toronto, Canada** – A new study published in the British Medical Journal suggests that a single dose of the existing MVA-BN vaccine offers significant protection against mpox infection. This discovery could be a crucial tool in the fight against the ongoing global mpox outbreak, which was declared a public health emergency by the World Health Organization last July.
The study, led by Public Health Ontario and the University of Toronto, analyzed data from over 6,000 men in Ontario, Canada. They compared 3,204 men who received a single dose of MVA-BN before potential exposure to mpox with an equal number of unvaccinated men. The results showed that the single dose of the vaccine was **58% effective in preventing mpox infection**.
This finding is particularly encouraging as it confirms the efficacy of a single dose of the vaccine, which is crucial considering the ongoing global supply constraints. The study also found that the vaccine’s effectiveness was delayed, with no noticeable protection in the first two weeks after vaccination, most likely due to the time needed for the body to develop sufficient antibody response.
“Our findings strengthen the evidence that MVA-BN is effective at preventing mpox infection and should be made available and accessible to communities at risk,” said lead researcher Christine Navarro.
The study utilized a novel approach called target trial emulation, which allowed for a rigorous analysis of observational data, minimizing the potential for bias.
This study adds valuable real-world data to the ongoing efforts to control the mpox outbreak. It emphasizes the importance of vaccination as a key strategy for preventing the disease and highlights the potential of existing vaccines in the fight against emerging infectious diseases.
First Piper 